QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:AURA

Aura Biosciences (AURA) Stock Forecast, Price & News

$12.66
-0.17 (-1.33%)
(As of 06/8/2023 ET)
Compare
Today's Range
$12.60
$13.02
50-Day Range
$8.51
$13.33
52-Week Range
$8.13
$24.83
Volume
45,174 shs
Average Volume
99,722 shs
Market Capitalization
$478.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

Aura Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
89.6% Upside
$24.00 Price Target
Short Interest
Bearish
6.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.97) to ($2.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

869th out of 981 stocks

Biological Products, Except Diagnostic Industry

143rd out of 163 stocks


AURA stock logo

About Aura Biosciences (NASDAQ:AURA) Stock

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.

Receive AURA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AURA Stock News Headlines

BTIG Keeps Their Buy Rating on Aura Biosciences Inc (AURA)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
8-K: Aura Biosciences, Inc.
Recap: Aura Biosciences Q1 Earnings
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Aura Biosciences (AURA) & Its Peers Head-To-Head Survey
Head-To-Head Survey: Aura Biosciences (AURA) & Its Rivals
Financial Survey: Aura Biosciences (AURA) and Its Peers
JMP Securities Reaffirms Their Buy Rating on Aura Biosciences Inc (AURA)
Why Shares of Aura Biosciences Jumped This Week
See More Headlines

AURA Price History

AURA Company Calendar

Last Earnings
5/11/2023
Today
6/08/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AURA
Fax
N/A
Employees
52
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+89.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-58,760,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.67 per share

Miscellaneous

Free Float
35,570,000
Market Cap
$478.55 million
Optionable
Not Optionable
Beta
0.09

Key Executives

  • Dr. Elisabet de los Pinos Ph.D. (Age 49)
    Founder, CEO, Pres & Director
    Comp: $676.62k
  • Ms. Julie B. Feder (Age 53)
    CFO, Sec. & Treasurer
    Comp: $505.45k
  • Dr. Cadmus Collins Rich CPE (Age 58)
    M.B.A., M.D., MBA, Chief Medical Officer and Head of R&D
    Comp: $564.22k
  • Dr. Mark A. De Rosch Ph.D. (Age 59)
    Chief Operating Officer
  • Mr. Paulo Carvalho
    VP of Technical Operations
  • Mr. Joseph Lyons
    VP of HR
  • Ms. Michele Keough M.B.A.
    Sr. VP of Project Management and Device Supply Chain













AURA Stock - Frequently Asked Questions

Should I buy or sell Aura Biosciences stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aura Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AURA shares.
View AURA analyst ratings
or view top-rated stocks.

What is Aura Biosciences' stock price forecast for 2023?

1 analysts have issued twelve-month price targets for Aura Biosciences' stock. Their AURA share price forecasts range from $24.00 to $24.00. On average, they predict the company's stock price to reach $24.00 in the next year. This suggests a possible upside of 89.6% from the stock's current price.
View analysts price targets for AURA
or view top-rated stocks among Wall Street analysts.

How have AURA shares performed in 2023?

Aura Biosciences' stock was trading at $10.50 at the beginning of the year. Since then, AURA shares have increased by 20.6% and is now trading at $12.66.
View the best growth stocks for 2023 here
.

When is Aura Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our AURA earnings forecast
.

How were Aura Biosciences' earnings last quarter?

Aura Biosciences, Inc. (NASDAQ:AURA) posted its quarterly earnings results on Thursday, May, 11th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.52) by $0.06.

What ETFs hold Aura Biosciences' stock?

ETFs with the largest weight of Aura Biosciences (NASDAQ:AURA) stock in their portfolio include AltShares Event-Driven ET (EVNT) and ALPS Medical Breakthroughs ETF (SBIO).BlackRock Future Health ETF (BMED).

When did Aura Biosciences IPO?

(AURA) raised $81 million in an initial public offering on Friday, October 29th 2021. The company issued 5,400,000 shares at $14.00-$16.00 per share.

What is Aura Biosciences' stock symbol?

Aura Biosciences trades on the NASDAQ under the ticker symbol "AURA."

Who are Aura Biosciences' major shareholders?

Aura Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.52%), Price T Rowe Associates Inc. MD (1.88%), Regency Capital Management Inc. DE (1.44%), Citigroup Inc. (1.37%), Geode Capital Management LLC (1.21%) and FMR LLC (0.94%). Insiders that own company stock include Cadmus Rich, David Michael Johnson, Julie B Feder, Matrix Capital Management Comp and Rosch Mark De.
View institutional ownership trends
.

How do I buy shares of Aura Biosciences?

Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aura Biosciences' stock price today?

One share of AURA stock can currently be purchased for approximately $12.66.

How much money does Aura Biosciences make?

Aura Biosciences (NASDAQ:AURA) has a market capitalization of $478.55 million. The company earns $-58,760,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis.

How can I contact Aura Biosciences?

The official website for the company is www.aurabiosciences.com. The company can be reached via phone at 617-500-8864 or via email at aura@argotpartners.com.

This page (NASDAQ:AURA) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -